Home ›
Triple Negative (TNBC) Breast Cancer Trials ›
NCT07876557
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.
Trial Details
NCT ID NCT07876557
Phase PHASE2
Sponsor Shanghai Junshi Bioscience Co., Ltd.
Status RECRUITING
Cancer Type Triple Negative (TNBC) Breast Cancer
Interventions JS212 in combination with JS207 JS212 monotherapy JS212 in combination with JS001
Locations (sample) Beijing, Beijing Municipality, China|39.9075,116.39723 Beijing, Beijing Municipality, China|39.9075,116.39723 Fuzhou, Fujian, China|26.06139,119.30611 Lanzhou, Gansu, China|36.05701,103.83987 Guangzhou, Guangdong, China|23.11667,113.25
Key Eligibility Criteria
Male or female age 18-70 years old; Voluntary participation in clinical study; Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression); No prior systemic antitumor therapy for locally advanced or Metastatic TNBC(cohort expansion period); only one line of prior systemetic treatment f…
For full eligibility, visit ClinicalTrials.gov .